LSTA

Business Context and Reporting Period

Company: NeoStem, Inc. (filing as LISATA THERAPEUTICS, INC. in metadata, but identified as NeoStem in text)
Reporting Period: Quarter and nine months ended September 30, 2009
Business Overview: NeoStem operates a network of adult stem cell collection centers and is developing stem cell therapies, including VSEL technology. The company is aggressively expanding operations in China through a Wholly Foreign Owned Enterprise (WFOE) and Variable Interest Entities (VIEs).
Key Event: On October 30, 2009 (subsequent to the period end), the company consummated a merger with China Biopharmaceuticals Holdings, Inc. (CBH), acquiring a 51% interest in Suzhou Erye Pharmaceuticals Company Ltd.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased to $157,709 for the nine months ended Sept 30, 2009, compared to $49,469 in the same period in 2008. This was driven by stem cell collection and storage fees.
• Expense Surge: Selling, general, administrative, and research expenses increased by 102% to $13.8 million. Significant drivers included:
  • Merger Costs: $2.2 million in legal and professional fees related to the CBH merger.
  • China Expansion: $2.5 million in expenses for establishing operations, including rent, legal fees, and consulting.
  • Equity Compensation: $3.8 million in non-cash charges for stock and options issued for services.
• Liquidity Improvement: Cash balances increased from $430,786 at year-end 2008 to $5.8 million at Sept 30, 2009, primarily due to $15.7 million in net proceeds from private placements of Series D Preferred Stock and warrants.
• Accounting Policy Change: The company modified its revenue recognition policy for license fees from physicians, recognizing them ratably over the license term rather than upfront. The impact on net loss was deemed immaterial.

Outlook, Risks, and Unusual Items

• Merger Completion: The merger with CBH closed on October 30, 2009. This transaction is expected to provide a revenue-generating pharmaceutical business but requires significant integration and regulatory approvals in China.
• Capital Needs: Management explicitly states that the merger and China expansion will not generate sufficient cash flow in the near term to support operations. The company anticipates a need for substantial additional capital, which may be dilutive or involve restrictive covenants.
• China Regulatory Risk: Stem cell research is categorized as "prohibited" for foreign investors in China. The company relies on a VIE structure to operate, which carries inherent legal and regulatory risks.
• Series D Conversion: Following shareholder approval in October 2009, 1.29 million shares of Series D Preferred Stock automatically converted into approximately 12.9 million shares of Common Stock, eliminating the 10% annual dividend obligation.
• Executive Changes: Mark Weinreb resigned as President in October 2009. New employment agreements were signed with key executives including the CEO, CFO, and General Counsel, involving significant equity grants.

Investor Verification Checklist

• Merger Integration: Verify the status of PRC regulatory approvals required for the joint venture with Suzhou Erye Pharmaceuticals and the effectiveness of the revised Joint Venture Agreement.
• Liquidity Runway: Assess the company's cash burn rate against the $5.8 million cash balance to determine the timeline for the next capital raise.
• VIE Structure Validity: Review the legal enforceability of the Variable Interest Entity agreements in China, given the "prohibited" status of foreign investment in stem cell research.
• Dilution Impact: Analyze the impact of the Series D conversion, the new equity grants to executives, and the potential exercise of 18.2 million outstanding warrants on future earnings per share.
• Revenue Sustainability: Confirm the growth trajectory of the stem cell collection network and the timeline for commercialization of VSEL technology.